Takeda’s Exkivity (mobocertinib) Receives NMPA’s Approval for EGFR Exon20 Insertion+ NSCLC
Shots:
- Exkivity, a tyrosine kinase inhibitor has received NMPA approval in China for the treatment of adult patients with LA or metastatic NSCLC who have EGFR Exon20 insertion mutations and whose disease has progressed on or after Pt-based CT
- The approval was based on the P-I/II trial (EXKIVITY) results evaluating Exkivity (160mg) in 114 patients with EGFR Exon20 insertion+ NSCLC which showed a confirmed ORR (28%) per IRC as well as an m-DoR of 15.8mos. per IRC, m-OS (20.2mos.) and a m-PFS (7.3mos.) & also showed a clinical meaningful and durable responses
- The therapy is currently approved in the US, Great Britain, Switzerland, South Korea, Australia, and China for the same indication
Ref: Business Wire | Image:Takeda
Related News:- Takeda's Exkivity (mobocertinib) Receives the US FDA's Approval as the First Oral Therapy for EGFR Exon20 Insertion+ NSCLC
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
